Usefulness of the CHA2DS2-VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With Atrial Fibrillation - 25/01/19
, Chia-Jen Liu, MD c, d, Su-Jung Chen, MD d, e, Ta-Chuan Tuan, MD a, b, Yenn-Jiang Lin, MD a, b, Shih-Lin Chang, MD a, b, Li-Wei Lo, MD a, b, Yu-Feng Hu, MD a, b, Fa-Po Chung, MD a, b, Jo-Nan Liao, MD a, b, Tzeng-Ji Chen, MD f, Gregory Y.H. Lip, MD g, ⁎ , Shih-Ann Chen, MD a, bRésumé |
Sudden cardiac death (SCD), the most devastating manifestation of ventricular arrhythmias (VAs), is the leading cause of mortality in patients with atrial fibrillation (AF). We hypothesized that the CHA2DS2-VASc score, consisting of age and several clinical risk factors, could be used to estimate the individual risk of SCD/VAs for AF patients. From year 2000 to 2011, 288,181 newly-diagnosed AF patients without antecedent SCD/VAs were identified from “Taiwan National Health Insurance Research Database.” During the follow-up of 1,065,751 person-years, 11,166 patients experienced SCD/VAs with an annual risk of 1.05% which increased from 0.34% for patients with a CHA2DS2-VASc score of 0% to 2.63% for those with a score of 9. The CHA2DS2-VASc score was a significant predictor of SCD/VAs with an adjusted hazard ratio of 1.21 (95% confidence interval 1.20 to 1.22) per 1 point increment of the score. As the CHA2DS2-VASc score increased from 1 to 9, the hazard ratio of SCD/VAs continuously increased from 1.28 to 4.17 compared with patients with a CHA2DS2-VASc score of 0. In conclusion, CHA2DS2-VASc score was a convenient scoring system which could be used to predict the risk of SCD/VAs in AF patients in addition to its ability for stroke risk stratification.
Le texte complet de cet article est disponible en PDF.Plan
| This work was supported in part by grants from the Ministry of Science and Technology (MOST 104-2314-B-075-024-MY3), and Taipei Veterans General Hospital (V105B-023). This study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health or National Health Research Institutes. |
Vol 122 - N° 12
P. 2049-2054 - décembre 2018 Retour au numéro
Article précédent
- Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention
- Na Xu, Xiao-fang Tang, Yi Yao, Xue-yan Zhao, Jue Chen, Zhan Gao, Shu-bin Qiao, Yue-jin Yang, Run-Lin Gao, Bo Xu, Jin-Qing Yuan
- Underuse of Oral Anticoagulants in Patients With Ischemic Stroke and Atrial Fibrillation in China
- Jian Guo, Tianjia Guan, Siyuan Fan, Baohua Chao, Longde Wang, Yuanli Liu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?